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Psychotic symptoms are frequent in late-onset Alzheimer’s disease (LOAD) patients. Although the risk for
psychosis in LOAD is genetically mediated, no genes have been identiﬁed. To identify loci potentially
containing genetic variants associated with risk of psychosis in LOAD, a total of 263 families from the Na-
tional Institute of Aging-LOAD cohort were classiﬁed into psychotic (LOADþP, n ¼ 215) and nonpsychotic
(LOADeP, n ¼ 48) families based on the presence/absence of psychosis during the course of LOAD. The
LOADþP families yielded strong evidence of linkage on chromosome 19q13 (two-point [2-pt] logarithm of
odds [LOD] ¼ 3.8, rs2285513 and multipoint LOD ¼ 2.7, rs541169). Joint linkage and association in 19q13
region detected strong association with rs2945988 (p ¼ 8.7  107). Linkage results for the LOADeP
families yielded nonsigniﬁcant 19q13 LOD scores. Several 19q13 single-nucleotide polymorphisms
generalized the association of LOADþP in a Caribbean Hispanic (CH) cohort, and the strongest signal was
rs10410711 (pmeta ¼ 5.1  105). A variant located 24 kb upstream of rs10410711 and rs10421862 was
strongly associatedwith LOADþP (pmeta¼ 1.0 105) in ameta-analysis of the CH cohort and an additionalnd the Department of Neurology, Columbia University Medical Center and New York Presbyterian Hospital, New York,
18.
eux).
Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
S. Barral et al. / Neurobiology of Aging 36 (2015) 3116.e9e3116.e16 3116.e10non-Hispanic Caucasian dataset. Identiﬁed variants rs2945988 and rs10421862 affect brain gene expres-
sion levels. Our results suggest that genetic variants in genes on 19q13, some ofwhich are involved in brain
development and neurodegeneration, may inﬂuence the susceptibility to psychosis in LOAD patients.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Psychotic symptoms, hallucinations and delusions, are frequent in
patients with late-onset Alzheimer’s disease (LOAD). Multiple studies
suggest that the frequency of psychosis in patients with LOAD
(LOADþP) is close to 50%. With estimates of >13 million Americans
affected by LOAD by 2050 (Thies and Bleiler, 2013), LOADþPwould be
among the most prevalent psychotic disorders in the United States.
Compared with LOAD patients without psychosis (LOADeP),
patients with LOADþP demonstrate more severe cognitive and
functional deﬁcits (Scarmeas et al., 2005), more rapid cognitive
decline (Sweet et al., 2012), and more prone aggressive behaviors
(Sweet et al., 2000). Patients with LOADþP progress to more
advanced stages of disease with worse general health (Bassiony
et al., 2000), greater rates of institutionalization (Lopez et al.,
1999), and increased mortality (Wilson et al., 2006).
There is strong evidence for familial aggregation of psychosis in
patients with LOAD. In a previous study of familial aggregation of
LOADþP in a cohort of patients and their siblings with AD (Sweet
et al., 2002), we showed that the occurrence of psychotic symptoms
in siblings with LOAD was 3 times that of the siblings of patients
without psychosis. Additional studies have supported the familial
aggregation of LOADþP (Hollingworth et al., 2007). The estimated
heritability of psychosis in LOAD is 61% when psychosis is deﬁned by
the presence of multiple or recurrent psychotic symptoms and is 30%
for any single occurrence of a symptom (Bacanu et al., 2005). Subse-
quent linkage and association studies to identify genetic variants
associated with the combined LOADþP phenotype have detected
linkage to chromosomes 2p, 6q, 7q, and 15q (Avramopoulos et al.,
2005; Bacanu et al., 2002; Go et al., 2005; Hollingworth et al., 2007).
Initial efforts to identify genetic variants contributing to LOADþP
used a candidate gene approach, focused on the APOE locus and on
genes implicated in alterations in the serotonergic, dopaminergic, and
catecholaminergic neurotransmission systems (DeMichele-Sweet and
Sweet, 2010). Results for the APOE locus have been inconsistent but
predominantly negative (DeMichele-Sweet and Sweet, 2010). More
recently, the ﬁrst genome-wide association study (GWAS) of LOADþP
was reported (Hollingworth et al., 2012), a meta-analysis of 3 LOAD
GWAS datasets comprising 1299 cases with LOADþP, 735 with
LOADeP, and 5659 unaffected controls. This analysis identiﬁed several
loci with strong evidence of association with LOADþP, although no
single locus reached the threshold for genome-wide signiﬁcance.
We hypothesized that a distinct genetic mechanism raises risk
for LOAD with an increased likelihood of comorbid psychosis. To
test this hypothesis, we divided a large set of LOAD families into 2
groups based on the presence/absence of psychosis during the
course of LOAD in at least 1 individual. Then, we carried out
linkage analysis separately within each set of families.2. Materials and methods
2.1. Study participants
2.1.1. National Institute of Aging LOAD Cohort
2.1.1.1. Standard protocol approvals, registrations, and patient con-
sents. Informed consent for the study was obtained for allparticipants. Recruitment for the National Institute of Aging (NIA)-
LOAD study was approved by the relevant institutional review
boards of the participating centers. The study was conducted ac-
cording to the principles expressed in the Declaration of Helsinki.
Description of the recruitment, diagnostic procedures, and the
approach to characterization of psychotic symptoms for the NIA-
LOAD cohort has been described previously (Sweet et al., 2010). In
brief, qualifying families required a proband and a full sibling, each
with a diagnosis of deﬁnite or probable Alzheimer’s disease
(McKhann et al., 1984) with onset after 60 years of age and at least 1
additional biologically related family member who was 60 years or
older if unaffected or 50 years or older if diagnosed as having AD or
mild cognitive impairment (Petersen et al., 1999). Psychosis was
assessed by interview of a knowledgeable informant and rated on the
Consortium to Establish a Registry for Alzheimer’s Disease Behavioral
Rating Scale 1996 version (Mack et al., 1999), the Neuropsychiatric
Inventory (Cummings et al., 1994), and the Neuropsychiatric In-
ventory Questionnaire (Kaufer et al., 2000), with slight modiﬁcation
as described previously (Sweet et al., 2010). We have previously
established excellent interrater reliability of psychosis using this
approach to assessment in this cohort (Sweet et al., 2010).
Delusionsweredeﬁnedaspersistent falsebeliefsbasedon incorrect
inference about external reality, resistant to persuasion or contrary
evidence, and not attributable to social or cultural mores. Hallucina-
tionsweredeﬁnedas sensoryperceptions forwhich therewasnobasis
in reality. Discrete hypnagogic and hypnopompic hallucinations, as
well as symptoms occurring only during an episode of delirium, were
not rated. To avoid phenocopies because of momentary confusion or
misinterpretation by the observer, a delusion or hallucination was
deﬁned by its persistence over time. Thus, a given Consortium to
Establish a Registry for Alzheimer’s Disease Behavioral Rating Scale
item is considered evidence of a delusion or hallucinationwhen it was
rated as occurring (at least) 3 times in the past month at any visit.
Because the frequency of psychosis in LOAD increases in individuals
with a Clinical Dementia Rating (CDR) Scale score >1 (Sweet et al.,
2010), classiﬁcation as not psychotic required individuals to be free of
delusionsandhallucinations throughout their illness and tohaveaCDR
>1. Using this deﬁnition, we found that LOADþP is a highly heritable
trait (h2 ¼ 0.61, standard error ¼ 0.31) in the NIA-LOAD cohort (for a
description of heritability analysis, see Supplementary Methods),
supporting its use for the gene-mapping analyses we conducted.
For the present analysis, we used a sample of 607 families from the
NIA-LOADcohort thatwaspreviouslyusedinagenome-wideanalysisof
familial LOAD (Wijsman et al., 2011). We furthermore restricted the
analysis to familieswheremembershadpsychosisassessmentsandalso
available genome-wide data, leading to a ﬁnal sample of 1279 subjects
from263 families. The familieswere divided into 2 subgroups based on
the presence or absence of psychosis symptoms in LOAD family mem-
bers. Familieswith at least 1 LOAD familymemberwith psychosiswere
classiﬁed as LOADþP families (n ¼ 215). Families without any LOAD
members with psychosis were classiﬁed as LOADP families (n¼ 48).
2.2. Statistical analyses
2.2.1. Genome-wide genotyping of NIA-LOAD cohort
Genotyping of the study participants was performed using
Illumina Human610Quadv1_B BeadChips (Illumina, San Diego, CA,
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restricted to single-nucleotide polymorphism (SNP) markers with
minor allele frequencies of 5%.
2.2.2. Linkage analysis
To evaluate the evidence for linkage in the LOADþP and LOADP
families, we performed nonparametric two-point (2-pt) genome-
wide linkage analysis using the Kong and Cox linear model imple-
mented in multipoint engine for rapid likelihood inference
(Abecasis et al., 2002). Linkage analyses performed in both LOADþP
and LOADP families were carried out using sex, age, education,
and CDR as covariates. We have included CDR score because func-
tional severity of dementia has been associated with the presence
of psychosis in patients with LOAD (Sweet et al., 2010). Evidence for
linkagewas considered statistically signiﬁcant in the 2-pt analysis if
the 2-pt LOD score was 3.6 (Lander and Kruglyak, 1995). We
performed multipoint (mpt) linkage analysis in regions with sig-
niﬁcant linkage evidence in the 2-pt analysis. Because the presence
of linkage disequilibrium among SNPs violates an underlying
assumption of mpt linkage analysis software, SNPs were pruned on
the basis of a correlation coefﬁcient, r2, of 0.2 using PLINK software
(http://pngu.mgh.harvard.edu/wpurcell/plink/index.shtml).
2.2.3. Test of linkage heterogeneity
To test for linkage heterogeneity between the LOADþP and
LOADP families, we used an approach based on the heterogeneity
test of Morton (1956). First, we performed linkage analysis in all
LOADþP and LOADP families combined, to obtain the maximum
LOD score under the null hypothesis of homogeneity (Zmax, com-
bined). Second, we performed linkage analysis within each family
subgroup separately, obtained the maximum LOD score for each
SNP, Zmax, LOADþP and Zmax, and LOADP, and then summed these
2 maximum values. The chi-square statistic for the test for het-
erogeneity was computed as c2(1) ¼ 4.6  ([Zmax, LOADþP þ Zmax,
LOADP]  Zmax, combined).
2.2.4. Linkage power calculation
To estimate the power of our LOADeP families in detecting
linkage, we performed simulations of genotypes for 100 replicates
using SLINK (Ott, 1989). We assumed an autosomal dominant in-
heritance model, recombination fraction ranging from 0.0 to 0.45
and minor allele frequencies ranging from 10% to 40%.
2.2.5. Joint linkage and association analysis
For chromosomal regions that yielded signiﬁcant 2-pt LOD
scores and mpt LOD scores 2.5, we carried out joint linkage and
association analysis in a 50-kb region encompassing the linkage
peaks using PSEUDOMARKER software (Gertz et al., 2014). Adjust-
ment for multiple testing based on the 157 SNPs tested on 19q13.12
was carried out using Bonferroni correction (signiﬁcance threshold
p  3.7  104).
2.2.6. Generalization cohort
Because the frequencies of genetic variants can differ substan-
tially between different ethnic groups, it is important to assess
whether results obtained in populations of European ancestry can
be extended to populations of different ancestry. Hence, we
assessed whether our results can be generalized using a Caribbean
Hispanic (CH) sample, Estudio Familiar de Inﬂuencia Genetica en
Alzheimer (EFIGA), and Washington Heights-Inwood Columbia
Aging Project (WHICAP). Unrelated CH subjects were selected from
the WHICAP study and the EFIGA. WHICAP is a population-based
study of elderly individuals residing in New York, and EFIGA
study recruited CH families with multiple members affected with
LOAD. Both studies followed the same clinical diagnostic methods,and both cohorts have been described elsewhere (Mayeux et al.,
2001; Vardarajan et al., 2014). For analysis purposes, we identi-
ﬁed unrelated individuals as psychotic based on the presence of one
or more of the following rated as present on the medical history
form: (1) psychosis identiﬁed as the ﬁrst symptom of dementia; (2)
hallucinations (visual, auditory, olfactory, or tactile); (3) delusions;
and (4) receipt of anti-psychotic medication. In this analysis, we
have included 4917 study’s participants from 3 different and in-
dependent recruitment waves (CH1, CH2, and CH3).
2.2.7. Genome-wide genotyping
Genome-wide genotyping was done using 2 high-throughput
SNP genotyping platforms: Illumina HumanHap 650Y platform
and Omni Express.
2.2.8. Test of SNP association in the CH sample
For generalization purposes, the 19q13.12 regionwas deﬁned by
a total of 246 SNPs that were within the region of interest and
genotyped in the 3 CH datasets. To account for the effects of pop-
ulation substructure, we performed a principal components anal-
ysis using EIGENSTRAT software (http://genepath.med.harvard.
edu/wreich/EIGENSTRAT.htm). Logistic regression models were
conducted using PLINK software (http://pngu.mgh.harvard.edu/
wpurcell/plink/index.shtml). All analyses were adjusted for sex,
age, and the ﬁrst 10 principal components derived from the
EIGENSTRAT analysis.
2.2.9. Meta-analysis of the CH datasets
The 3 independent datasets were combined into ameta-analysis
taking into account study-speciﬁc sample size and direction of the
association effect using METAL software (http://www.sph.umich.
edu/csg/abecasis/metal/). Adjustment for multiple testing was
carried out using Bonferroni correction.
2.2.10. Replication cohort: University of Pittsburgh Alzheimer
Disease Research Center
To further replicate associations in an independent dataset, we
used a non-Hispanic Caucasian (NHC) cohort recruited from the
University of Pittsburgh Alzheimer Disease Research Center. Char-
acterization of the psychotic symptoms and quality control of the
Alzheimer Disease Research Center genomic data has been
described in detail elsewhere (Hollingworth et al., 2012). For
analysis purposes, a total of 496 LOADþP and 156 LOADP subjects
were included.
2.2.11. Brain expression Quantitative Trait Loci (eQTL) analyses
To further determine whether associated SNPs affect gene
expression levels, we used the publically available dataset from the
UK Brain Expression Consortium that is based on tissue from 12
brain regions from 134 individuals free of neurodegenerative dis-
orders analyzed using the Affymetrix Exon 1.0 ST Array (http://
www.braineac.org/).
3. Results
Characteristics of the different study cohorts (NIA-LOAD, CH1,
CH2, CH3, and NHC) are provided in Supplementary Table 1.
The LOADþP families used for the linkage analysis consisted of
981 individuals from215 families, including 264 LOADpatientswith
psychotic symptoms and 279 without psychosis. The average age at
evaluation and standard deviation of the LOADþP family members
was 76  7 years, and 55% were women. The LOADP families
consisted of 298 individuals from 48 families, including 139 LOAD
patients without psychotic symptoms. The age at evaluation of the
LOADP family members was 76  8 years, and 53% were females.
S. Barral et al. / Neurobiology of Aging 36 (2015) 3116.e9e3116.e16 3116.e12Genome-wide linkage analysis of the LOADþP families identi-
ﬁed several regions with 2-pt LOD scores 3.6. The maximum 2-pt
LOD score was observed on chromosome 18q21.32, with LOD ¼ 4.9
at rs2332026 (90.18 cM); however, mpt linkage analysis of the re-
gion did not yield signiﬁcant evidence of linkage (maxLOD ¼ 2.0 at
rs7069001). There were 3 different chromosomal regions, 14q32,
16q21, and 19q13.12, that yielded 2-pt LOD scores 3.6 and mpt
LOD scores2.5 that were prioritized for additional analysis (Fig.1A
and B, Table 1). Joint linkage and association analysis of these 3
candidate regions (Fig. 1C, Table 1) identiﬁed SNP marker
rs2945988 at 19q13.12 as strongly associated with psychosis (p ¼
8.7  107) even after Bonferroni adjustment. Although additional
SNPs showed also nominal association with psychosis within the 2
other regions, rs10139111 at 14q32 (p ¼ 0.005) and rs9927943 at
16q21 (p ¼ 0.003), they did not survive correction for multiple
testing.
We focused on 19q13.12 signal because of its strong evidence of
linkage and association and tested linkage heterogeneity. We found
statistical evidence for the existence of heterogeneity between
LOADþP and LOADP families (p ¼ 0.011), further supporting the
need for stratifying the family cohort based on the presence or
absence of psychotic symptoms among the LOAD patients.
Our simulation results shown that when the linked allele fre-
quency is 37%, the frequency of the minor allele of SNP rs2945988
in the LOADP cohort of families, we will have 93% power to detectFig. 1. Results of the genome-wide linkage and association analyses. (A) Genome-wide nonp
psychosis (LOADþP) (right panel) and late-onset Alzheimer’s disease patients without psyc
somes, and y-axis corresponds to the individual single-nucleotide polymorphism (SNP)’s LO
wide signiﬁcant evidence of linkage (2-pt LOD scores 3.6) in the LOADþP families (right pa
represents physical location in base pair, and y-axis represents the individual SNP’s LOD sco
peak for chromosomal regions mpt LOD scores 2.5 in the LOADþP families; x-axis repres
recombination rate (cM/Mb), and the right y-axis corresponds to the logarithm of the p vaLOD scores exceeding the Lander and Kruglyak threshold for sig-
niﬁcant linkage (LOD  3.6).
To test whether our ﬁndings can be generalizable to another
ethnic group, we used a sample of unrelated subjects with CH
ancestry (CH1, CH2, and CH3) that included 231 LOAD patients with
psychotic symptoms and 1943 without psychosis. Logistic regres-
sion analysis (age, sex, and population stratiﬁcation adjusted)
identiﬁed several SNPs as strongly associated with the LOADþP
phenotype after adjustment for multiple testing with Bonferroni
correction (Fig. 2 and Supplementary Table 2). The strongest signal
with the same effect direction in all 3 CH datasets was found for SNP
rs10410711 (pmeta ¼ 5  105), an intronic variant in ZNF566 gene.
Additional variants in this gene also survived multiple testing cor-
rections and achieved signiﬁcant LOADþP association: rs10421862,
located 24 kb downstream (pmeta ¼ 5  105) showed same direc-
tion of the association in the 3 CH cohorts and rs10419962
(pmeta ¼ 4.7  105), 234 kb upstream, showed same direction of
the association in CH1 and CH2.
We interrogated 19q13.12 region, deﬁned by a total of 246 SNPs,
in an independent NHC dataset. First, we analyzed the results from
CH and NHC datasets via trans-ethnic meta-analysis usingMANTRA
software (Morris, 2011). Results from MANTRA revealed little evi-
dence of heterogeneity in allelic effects of the SNPs (posterior
probability of heterogeneity <50%) between the different pop-
ulations, that is, the most heterogeneous SNP in terms of allelicarametric 2-point (2-pt) linkage analysis in late-onset Alzheimer’s disease patients with
hosis (LOADP) (left panel) families; x-axis represents each of the analyzed chromo-
D score. (B) Multipoint (mpt) linkage analysis in chromosomal regions with genome-
nel) and mpt linkage analysis of the same chromosomes in the LOADP families; x-axis
re. (C) Joint linkage and association analysis in 50 kb region encompassing the linkage
ents base pair position (Mb) along the chromosome, the left y-axis corresponds to the
lue.
Fig. 2. Generalization of 19q13.12 region in Caribbean Hispanic (CH) cohorts. Multivariate regression results from 3 independent CH replication cohorts and their meta-analysis;
x-axis represents physical location of the single-nucleotide polymorphism markers in kilobases, and y-axis represents logarithm of the p value obtained in the analyses.
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34%. As SNPs in CH and NCH cohorts share a common effect size, we
meta-analyzed the results with a ﬁxed-effect model approach using
METAL software (http://www.sph.umich.edu/csg/abecasis/metal/).
The strongest association with LOADþP phenotype corresponds to
rs10421862 (pmeta ¼ 1.0  105), with the same effect direction in
CH and NHC datasets (data not shown).
SNP rs2945988 identiﬁed in the NIA-LOAD cohort was not sta-
tistically signiﬁcant in the CH meta-analysis (p ¼ 0.063). However,
SNPrs2945988 in NIA-LOAD and its closest variant in CH,
rs10421862, located 45 kb apart, are in low linkage disequilibrium
(r2 ¼ 0.10), which would be expected based on the different linkage
disequilibrium patterns within this chromosomal region between
European and Hispanics ancestry populations (Supplementary
Fig. 1). Nevertheless, the location would suggest that a gene or set
of genes in this region are likely to underlie psychosis in patients
with LOAD.
Results from eQTL analyses using BRAINEAC showed that 73
genes within the 19q13.12 region had also altered brain expression
because of these 2 19q13.12 variants, rs2945988 and rs10421862Table 1
Candidate regions from genome-wide linkage and association analyses of the
LOADþP families
Band SNP 2-pt LOD SNP mpt LOD SNP pjoint
14q32 rs3742339 4.4 rs5508 2.5 rs10139111 0.005
16q21 rs1867612 3.6 rs9302724 2.6 rs9927943 0.003
19q13.12 rs2285513 3.8 rs541169 2.7 rs2945988 8.7  107
LOADþP, late-onset Alzheimer’s disease patients with psychosis; SNP, single-
nucleotide polymorphism.(Supplementary Table 3). After Bonferroni multiple testing adjust-
ment (p  6.8  104), rs2945988 is a signiﬁcant gene-level cis-
eQTL for ZNF461 (p ¼ 2.2  105) and ZFP82 (p ¼ 8.0  105). Both
genes are expressed in brain and codify Krüppel-associated box-
containing zinc-ﬁnger proteins, the largest family of transcrip-
tional regulators in the human genome (Urrutia, 2003).
4. Discussion
To identify loci potentially containing genetic variants associated
with higher risk of developing psychosis in subjects affected by
LOAD, we performed a genome-wide linkage analysis in a sample of
NIA-LOAD families in which some members with LOAD also
exhibited psychosis symptoms.We observed signiﬁcant evidence for
2-pt andmpt linkages on chromosome 19q13.12 (2-pt LOD¼ 3.8 and
mpt LOD ¼ 2.7). Further investigation of the linkage signal using
joint linkage and association analyses identiﬁed SNP rs2945988 as
strongly associatedwith psychosis (pjoint¼ 8.7107). The 19q13.12
associationwith psychosis was generalized to a sample of unrelated
Alzheimer’s patients and controls of CH ancestry rs10410711
(pmeta¼ 5105). Further evidencewas achieved through themeta-
analysis of the CHs and an independent NHC cohorts, where another
19q13.12 variant located 24 kb upstream rs10410711, rs10421862,
appeared strongly associatedwith LOADþP (pmeta¼ 1.0105) with
the same effect direction in all datasets.
In themost recent genome-wide linkage analysis of LOADþPup to
date, Hollingworth et al. (2007) reported chromosome- and genome-
wide signiﬁcant linkage peaks on chromosomes7 and15.Despite the
differences in their study design (linkage analysis was restricted to
affected relative pairs) and clinical assessment of psychosis (limited
data were available covering the presence, type, and severity of
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to chromosome 19 at 50 cM, being the nearest marker D19S433
(30,417,027e30,417,232),w5 Mb upstream 19q13.12 region.
Recent studies evaluating the genetic contributions to LOADþP
have consisted of GWAS approaches. Hollingworth et al. (2012)
undertook a meta-analysis of 3 GWASs to identify loci LOADþP
loci. The possible association between chromosome 19 and
LOADþP is limited to APOE locus (located >10 Mb apart from the
identiﬁed 19q13.12 region). However, as previously reported
(Demichele-Sweet et al., 2011), no evidence of association was
observed at the APOE locus when analyzing LOADþP versus
LOADeP. They also identiﬁed genetic variants/genes revealed
overlap with other psychiatric disorders with psychotic features.
In the ﬁrst genome-wide study of copy number variation to date,
Zheng et al. (2015) identiﬁed a signiﬁcant duplication in the APC2
gene on 19p13, which was protective against developing LOADþP.
Their results also suggested that the same genetic variants (SNPs
and copy number variations) may be implicated in different psy-
chiatric disorders (schizophrenia, autism, and LOADþP).
To that end, the identiﬁed 19q13.12 variants in this study,
rs2945988 and rs10421862, are located within zinc-ﬁnger binding
proteins, ZNF260 and ZNF566, respectively, with a plausible role as
regulators of gene expression. Of interest, several recent genetic
association studies have reported that variants in a zinc-ﬁnger
protein gene, ZNF804A, strongly inﬂuence susceptibility to psy-
chosis, schizophrenia, and bipolar disorder (Steinberg et al., 2011).
Additional studies have implicated genomic variation in 19q13.12
as risk factor for neuropsychiatric disorders. Xu et al. (2008) reported
a de novo deletion on chromosome 19q13.12 with relatively high
penetrance that contributes to the genetic component of schizo-
phrenia. A multistage schizophrenia GWAS (SchizophreniaWorking
Group of the Psychiatric Genomics Consortium, 2014) identiﬁed 128
independent associations spanning 108 conservatively deﬁned loci.
Among the signiﬁcant loci was an SNP on chromosome 19q13.12,
mapping 13 Mb upstream of our identiﬁed region.
Brain eQTL analyses revealed that SNP rs2945988 signiﬁcantly
affects gene expression of 2 Krüppel-associated box-containing
zinc-ﬁnger genes (ZNF461 and ZFP82), suggesting transcriptional
regulation as possible functional mechanism. Although they
represent plausible a priori functional candidates for LOADþP,
there is no guarantee that they are the causal genes; thus, it is
likely that other loci within this region contribute to psychosis
risk in LOAD (for genes in the 19q13.12 linkage region, see
Supplementary Fig. 2).
Among other potential candidate genes within this region
(Supplemental Fig. 2) are WDR62 and SNX26, both expressed in
brain and highly conserved. Assessment of brain expression pat-
terns also revealed that rs2945988 and rs10421862 nominally affect
the expression levels of the proteins encoded byWDR62 (p¼ 0.012)
and SNX26 (p ¼ 0.006) genes, respectively.
Mutations in theWD repeatecontaining protein 62 geneWDR62
have been reported as the cause of a wide spectrum of severe ce-
rebral cortical malformations. Experiments in human and mouse
embryonic brain found that its expression was restricted to neural
precursors undergoing mitosis, suggesting that WDR62 is a key
protein in neural precursor generation, a process that is uniquely
vital to human cerebral cortex growth (Nicholas et al., 2010).
The sorting nexin 26 gene (SNX26), a brain-enriched Rho
GTPase-activating protein, is involved in the regulation of dendritic
branching and neuronal complexity in the developing brain and
also affects synaptic plasticity in mature neurons. Dendritic spines
changes are closely associated with various neurologic diseases
(Kim et al., 2013).
Our results suggest that the locus at 19q13.12 may inﬂuence the
risk of developing a form of LOAD associated with psychosis. Ourgeneralization sample consisted of a population-based cohort of CH
subjects. Because of differences in genetic ancestry between
European and Hispanic populations, we would not necessarily
expect the same SNPs to be associated with LOADþP in both pop-
ulations, although different SNPs in the same region might show
association. Our observation of association of LOADþP with several
SNPs in the same region in CHs and NHC, despite the differences
between European and Hispanic samples in environmental and ge-
netic factors, strengthens the evidence for 19q13.12 as susceptibility
locus for psychosis in LOAD patients. Similar generalization ap-
proaches have been previously reported in the literature. Graff et al.
(2013) used Hispanic population to investigate common adiposity-
related genetic loci previously reported in European descent pop-
ulations and provided evidence for the generalization of several body
mass index and central adiposity loci in Hispanic women.
Although a potential limitation of our study was the lack of
detailed assessments of the psychosis phenotype in the CH cohort,
the evidence for generalization of the linkage signal indicates that
the ﬁndings were robust and not related to the method of identi-
ﬁcation of the phenotype. Some of the subjects from the NIA-LOAD
family cohort were included in the GWAS meta-analysis conducted
by Hollingworth et al. (2012).
The fact that the identiﬁed LOADþP variants affect the brain
expression levels of the several genes in 19q13.12 region suggests
that their expression might be transcriptionally regulated. Whether
these variants are associated with the development of psychosis in
LOAD speciﬁcally or are associated also with psychosis in the
absence of LOAD is an interesting question that remains to be
investigated. Sequencing of the 19q13.12 region using the most
informative families may help to identify variants contributing to
susceptibility to LOAD and psychosis.
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